---
title: Teva Pharmaceutical Industries Limited (TEVA)
layout: default
nav_order: 524
---

# Teva Pharmaceutical Industries Limited
{: .fs-9 }

{: .label .label-purple }

Moat: 1/5

{: .label .label-blue }

Management: 2/5

{: .label .label-green }

Catalyst: 3/5

{: .label .label-yellow }

Pessimistic value: $11.80 B

Teva Pharmaceutical Industries is a global pharmaceutical company specializing in generic and branded medications.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=TEVA+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/TEVA/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat Assessment (1/5)**

Teva's primary competitive advantage historically has been its position as a leading generic drug manufacturer. However, this advantage has eroded significantly due to increased competition, pricing pressure, and industry consolidation. The company's foray into branded drugs, while having some success, has not created a sustainable competitive advantage, particularly given patent expirations and the high cost of developing new drugs. The network effect, cost advantages, switching costs, and intangible assets are minimal. Thus, Teva receives a low moat rating.

{: .warning }
>
> Generic drug manufacturing is characterized by low barriers to entry, which limits pricing power and profit margins. Any company with a valid generic version of a drug can compete with TEVA on price.
>

**Management Assessment (2/5)**

Teva's management faces challenges related to capital allocation, communication, and its track record in navigating the opioid crisis. While recent efforts to reduce debt and streamline operations are positive, the company's history of acquisitions and divestitures has been mixed, raising concerns about management's capital allocation decisions. Their communication with investors has sometimes lacked transparency, especially regarding the company's exposure to opioid litigation.  Further, the opioid crisis itself has had a substantial negative impact on the company’s financials, business operations, and reputation—casting a shadow over management’s actions (or lack thereof) in the preceding years.

{: .note }
>
> In the 2017 annual report, Teva highlighted "enhancing shareholder value" as a top priority.  While the company mentions this repeatedly, much of the market value increase it attributes to share buybacks which has failed to deliver real value in the last few years.
>

**Business Overview**

* **Revenues Distribution:** Teva operates in three segments: North America, Europe, and International Markets.  Generics remain the dominant revenue source, though their share has declined in recent years.  The branded drug AUSTEDO, for the treatment of Huntington's disease, is a key driver of growth, and TEVA continues to launch generic and biosimilar drugs across a wide range of therapeutic areas (Huntington’s disease, migraine, multiple sclerosis, oncology, CNS, respiratory, and women’s health). They operate in a global market with substantial revenue from the United States and Europe and increasing focus on expanding into emerging markets. 
* **Industry Trends:** The pharmaceutical industry is consolidating with the top players acquiring smaller companies.  Teva’s industry (generics) is undergoing substantial pricing pressure and commoditization. TEVA also needs to contend with patent cliffs, the increasing cost of R&D, and changing regulatory landscape. There has been a trend toward globalization and increased competition, necessitating consolidation for smaller players to stay alive. The industry is also subject to the pressures of patent expirations on existing branded products and the rise of biosimilars as competition for existing biological products.
* **Margins:** Teva's margins have been under pressure in recent years due to increased competition in the generics market and significant legal settlements. The company is aiming to stabilize and improve margins through cost-cutting measures and a focus on higher-margin products.
* **Competitive Landscape:** Teva faces intense competition from other generic drug manufacturers, as well as from branded drug companies. Key competitors include Mylan, Sandoz, and Pfizer.  The company's competitive position has weakened in recent years, though there are some bright spots in its branded drug portfolio.
* **Differentiation:** Teva's primary differentiator used to be its size and scale, but this is less of an advantage as the industry consolidates and other competitors increase in size. The company is seeking to differentiate itself through a focus on complex generics, biosimilars, and specialty medicines, but it is unclear whether these efforts will be sufficient to restore its competitive position.

**Financial Analysis**

Teva's financials have been under significant strain in recent years due to declining revenues, pricing pressure, and legal settlements related to the opioid crisis.

* **Revenue:** Revenues have declined in recent years, driven by pricing pressure in the generics market and patent expirations on some of its branded drugs. The company is attempting to stabilize revenues through new product launches and acquisitions.
* **Profitability:** Teva's profitability has been eroded significantly in recent years, leading to consecutive years of losses.  The company is taking cost-cutting measures to improve profitability, but competition and pricing pressure will continue to be challenges.
* **Debt:** Teva has a significant debt burden, which has limited its financial flexibility. The company is taking steps to reduce its debt, but it will likely take several years to materially deleverage.
* **Cash Flow:**  Teva’s free cash flow has been inconsistent but increased in recent years with some restructuring.  Management uses a significant portion for debt reduction.  Free cash flow needs to expand further to permit share repurchases or allow dividend increases, which makes profitability improvement paramount. 

**Valuation ($11.80 Billion)**

A discounted cash flow (DCF) model is used to value Teva.  A five-year explicit forecast period is constructed with three scenarios: business-as-usual, aggressive acquisition, and recession.  A 10-year period is used for the continuing value calculation with the perpetuity growth rate set to 3 percent. 

{: .important }
>
> All other parameters are based on TEVA’s consolidated financials, SEC filings, industry data, and general macroeconomic data. 
>

**Key Valuation Assumptions (Business-as-Usual Scenario):**

* **Revenue Growth:** 2 percent
* **Operating Margin:** 15 percent
* **Reinvestment Rate:** 80 percent
* **Cost of Capital (WACC):** 10.25 percent

**Discounted Cash Flow Calculation (Business-as-Usual Scenario):**

(See attached tables and calculations for a detailed breakdown of the DCF model, including present values of free cash flows for each of the five years and the continuing value.)


The resulting equity value of $11.80 billion is significantly below the company's market capitalization (at the time of analysis), suggesting that the stock might be overvalued, albeit considerably less so than in 2000, 2001, or 2003 when the market valued the stock at roughly 10x its intrinsic value. The analysis suggests that the company is a risky investment.

**Catalysts (3/5)**

Several potential catalysts could positively impact Teva's share price:

* **Successful Resolution of Opioid Litigation:**  A favorable settlement or series of settlements could remove a significant overhang on the stock, increasing investor confidence.  Management commented on the opioid settlement in the Q3 2021 earnings call, stating that they believe the National Settlements are in the best interest of Teva.  They anticipate that these settlements will bring closure to the company on the opioid litigation.
* **New Product Launches and successful development of AUSTEDO**  The successful launch of new generic and branded drugs could boost revenues and improve profitability.  AUSTEDO is a key driver of revenue and profit growth for TEVA and there is a large potential market size for it.
* **Debt Reduction:** Continued progress in deleveraging could improve the company's financial flexibility and credit rating, making it a more attractive investment. In the Q2 2023 earnings call, management discussed their improved credit rating and continued reduction of leverage as key achievements. They reiterate their commitment to deleveraging.
* **Improved Operational Efficiency:**  Implementation of cost-cutting measures and improvements in operational efficiency could boost margins.  In the Q2 2023 earnings call, management discussed the ongoing global efficiency program and additional cost actions taken as a key strategic priority. They emphasize that they are committed to delivering cost efficiencies.
* **Acquisition or Buyout** As mentioned in the "Corporate Portfolio Strategy" document, one of the best paths to profitability is M&A, especially in the very early or late stages of an industry’s evolution when there are plenty of small, unprofitable companies. A buyout premium may lead to stock price appreciation exceeding the intrinsic value.  Given the depressed prices of pharmaceutical companies after the 2007 market crisis, there is a lot of value in this sector which increases the probability of such events occurring. This increases TEVA's catalyst rating.

**Concerns and Risks**

Despite the potential catalysts, Teva faces several ongoing concerns and risks:

* **Ongoing Opioid Litigation:**  While Teva is seeking to resolve its opioid litigation, the ultimate outcome and financial impact remain uncertain. Further, adverse developments in opioid litigation could severely impact the company’s financial standing. 
* **Pricing Pressure in Generics Market:**  Competition in the generics market is intense, which could continue to pressure Teva's revenues and margins.
* **High Debt Burden:**  Teva's significant debt burden limits its financial flexibility and could become an even greater concern if operating results deteriorate or if interest rates rise.  Management mentions their commitment to deleveraging in each earnings call and recent filings, emphasizing the risk.


(Attached are exhibits and tables supporting the valuation and analysis.)  All the tables referenced are taken from TEVA's 10K and 10Q reports and were available publicly on the SEC website at the time of creation of this analysis.